No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Mark Taylor?

Mr. Mark T. Taylor

Managing Director, Phamaceuticals

ROTH Capital Partners LLC

Direct Phone: (949) ***-**** ext. ****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Company Description

ROTH is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, ROTH has regional offices in Boston, Chicago, Larkspur, Los Angeles, N ... more

Find other employees at this company (403)

Background Information

Employment History

Senior Vice President, Corporate Development and Investor Relations

Obagi Medical Products Inc


Oculus Innovative Sciences , Inc.


Chief Executive Officer and Board Member
Hallux Inc

Board Member
Medical Care Corporation


Bachelor of Science degree

Tulane University


Web References (70 Total References)

Mark ... [cached]

Mark Taylor

Mark Taylor has over 20 years in the specialty pharmaceuticals sector serving as a senior executive of several public companies, and as a sell-side pharmaceutical analyst.
Most recently, Mr. Taylor was Senior Vice President of Corporate Development for Obagi Medical Products Inc., the market share leader in physician-dispensed dermatologics. Valeant Pharmaceuticals International acquired Obagi in April 2013.
Prior to Obagi, Mr. Taylor was Vice President, Diagnostics for MP Biomedicals, LLC, a privately held global provider of infectious disease screening and confirmatory tests.
Mr. Taylor also served Roth Capital Partners for five years where he held the titles of Managing Director of Healthcare Banking and Senior Pharmaceutical Analyst.
Prior to Roth, Mr. Taylor was head of the largest division at ICN Pharmaceuticals Inc. (now Valeant Pharmaceuticals International) as Executive Vice President, North America. Under Mr. Taylor's leadership, ICN expanded its dermatology division by adding prescription products, physician dispensed skin care brands, and light activated devices to its portfolio.
Mr. Taylor also served as Vice President of Business Development at Watson Pharmaceuticals (now Allergan plc.), another large dermatology products provider. During this time Watson made its first foray into dermatology products by acquiring Oclassen Pharmaceuticals, Inc.
Mark is a graduate of Tulane University and serves on the board of Medical Care Corporation, a private company focused on Alzheimer's research and diagnosis.

Mark Taylor | ROTH Capital Partners | Institutional Sales | Investment Banking [cached]

Mark Taylor, Institutional Sales Professional t: 949-720-7133, e:

Joined ROTH: May 2011

CollaGenex Pharmaceuticals, Inc. Analyst Coverage [cached]

Mark Taylor

Mark Taylor ... [cached]

Mark Taylor

Roth Capital Partners [cached]

Mark Taylor

Mark Taylor, Managing Director
t: 949-720-5728, e:
Joined ROTH: April 2003

Similar Profiles

Other People with this Name

Other people with the name Taylor

Kerry Taylor
Wickhambrook School

Daniel Taylor
Numeric Investors LLC

Chris Taylor
Computer Concepts Limited

David Taylor
Ballard Chalmers Ltd

Sophie Taylor
K&L Gates LLP

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory